ClinicalTrials.gg

Program

neridronic acid

Also written as “Neridronate”, “Neridronic acid 100 mg” and “Neridronic acid”.

Its studies are mostly in Complex Regional Pain Syndromes · Reflex Sympathetic Dystrophy, led by 2 companies.

Furthest: phase 3, since Mar 25, 20156 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grünenthal40 open or runningphase 3since Mar 25, 2015Mar 25, 2015none ahead
Ambros Therapeutics22 open or runningphase 3since Sep 17, 2025Sep 17, 2025Dec 2027phase 3 · NCT07210515

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2015First study: phase 3 study in Reflex Sympathetic DystrophyNew to GrünenthalGrünenthal · NCT02402530 · 459 enrolled · United States, Germany, United Kingdom
  2. Nov 21, 2016Phase 3 study in Complex Regional Pain SyndromesGrünenthal · NCT02972359 · 580 enrolled · United States, Germany
  3. May 7, 20182 phase 3 studies in Complex Regional Pain SyndromesGrünenthal · NCT03560986, NCT03530345
  4. Sep 17, 2025Ambros Therapeutics's first study: phase 3 study in Complex Regional Pain SyndromesNew to Ambros TherapeuticsAmbros Therapeutics · NCT07210515 · 270 planned · United States
  5. Sep 24, 2026Phase 3 study in Complex Regional Pain SyndromesAmbros Therapeutics · NCT07857733 · 135 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Complex Regional Pain SyndromesAmbros Therapeutics · NCT07210515
  2. Dec 31, 2028Primary completion: phase 3 study in Complex Regional Pain SyndromesAmbros Therapeutics · NCT07857733

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07857733Complex Regional Pain Syndromes · United States3RecruitingAmbros TherapeuticsDec 31, 2028135
NCT07210515Complex Regional Pain Syndromes · United States3RecruitingAmbros TherapeuticsDec 2027270
NCT03560986Complex Regional Pain Syndromes · United States, Canada, Czechia and more3TerminatedGrünenthalAug 1, 2019267
NCT03530345Complex Regional Pain Syndromes · United States, Australia, France and more3TerminatedGrünenthalJul 31, 2019182
NCT02972359Complex Regional Pain Syndromes · United States, Germany3CompletedGrünenthalJan 9, 2019580
NCT02402530Reflex Sympathetic Dystrophy · United States, Germany, United Kingdom3CompletedGrünenthalAug 2016459

How it is read

Names in the registry

  • “Neridronate”, 2 entries
  • “Neridronic acid 100 mg”, 2 entries
  • “Neridronic acid”, 1 entry
  • “Neridronic acid 62.5 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.